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Retroviruses encode proteinases necessary for the proteolytic processing of the viral gag and gag-pol precursor proteins. These enzymes have been 
shown to be structurally and functionally related to aspartyl proteinases such as pepsin and renin. Cerulenin is a naturally occurring antibiotic, 
commonly used as an inhibitor of fatty acid synthesis. Cerulenin has been observed t  inhibit production f Rous sarcoma virus and murine leukae- 
mia virus by infected cells, possibly by interfering with proteolytic processing of viral precursor proteins. We show here that cerulenin inhibits 
the action of the HIV-1 proteinase in vitro, using 3 substrates: a synthetic heptapeptide (SQNYPIV) which corresponds to the sequence at the 
HIV-I gag p17/p24 junction, a bacterially expressed gag pr cursor, and purified 66 kDa reverse transcriptase. Inhibition of cleavage by HIV-1 
proteinase required preincubation with cerulenin. Cerulenin also inactivates endothiapepsin, a well-characterised fungal aspartyl proteinase, sug- 
gesting that the action of cerulenin isa function of the common active site structure of the retroviral and aspartic proteinases. Molecular modelling 
suggests hat cerulenin possesses several of the necessary structural features of an inhibitor of aspartyl proteinases and retroviral proteinases. Al- 
though cerulenin itself i  cytotoxic and inappropriate for clinical use, it may provide leads for the rational design of i hibitors of the HIV proteinase 
which could have application in the chemotherapy of AIDS. 
Retroviral proteinase inhibitor; Human immunodeficiency virus; Catalytic mechanism 
1. INTRODUCTION 
Retroviruses translate th ir proteins as several arge 
precursor proteins, which are cleaved proteolytically, 
to yield the individual functional proteins [1]. Process- 
ing of  the gag and gag-pol polyproteins i due to the ac- 
tion of  the virally encoded proteinase [2,3]. In HIV-1, 
the proteinase itself is encoded as part of  a large precur- 
sor, Pr l60 gag-p°~, produced by a ribosomal frame shift 
f rom the gag to pol reading frames, which avoids the 
stop codon at the 3 ' -end of  the gag reading frame [4]. 
Analysis of  the amino acid sequences for a number 
of  retroviral proteinases, suggested that the retroviral 
proteinase sequence corresponds to a single domain of  
an aspartyl proteinase, which would be active as a 
dimer, and have a very similar active site structure to 
the pepsin-like aspartic proteinases [5]. This prediction 
has recently been confirmed by X-ray crystallographic 
structure determinations for the proteinases from Rous 
sarcoma virus [6] and HIV-1 [7]. 
Cerulenin ((2S,3R)2,3-epoxy-4-oxo-7,10-dodecadi- 
enoylamide), an inhibitor of  fatty acid and sterol syn- 
thesis [8], inhibits the fatty acylation of  the glyco- 
proteins of  vesicular stomatitis virus [9] and significant- 
ly affects the production of  infectious Rous sarcoma 
virus [10] and murine leukaemia virus (MuLV) by cells 
infected in culture [ 11,12], with an apparent decrease in 
specific proteolytic cleavage of the Pr65 ga~ precursor 
protein, possibly due to inhibition of  the viral pro- 
teinase. While the present work was in progress, Pal et 
al. reported a similar effect on precursor processing in 
HIV-1 [13]. Cerulenin has also been found to inhibit 
processing of  antigenic proteins by antigen-presenting 
cells [14]. 
Here we demonstrate that cerulenin inhibits in vitro 
cleavage by recombinant HIV-1 proteinase [15] of  
HIV-1 gag and 66 kDa reverse transcriptase precursor 
proteins, and of a synthetic peptide containing the se- 
quence at the gag p17-p24 junction. A well- 
characterised pepsin-like aspartic proteinase is also 
shown to be inactivated by cerulenin and the rate of  in- 
activation is slowed by the presence of an active-site 
directed competitive inhibitor. 
Using the structure of  the active site of  a retroviral 
proteinase, we describe the structural features of 
cerulenin that are responsible for its effect on retroviral 
and aspartic proteinases, and the implications for the 
design of  novel proteinase inhibitors with clinical 
potential in the treatment of  AIDS. 
2. MATERIALS  AND METHODS 
Correspondence address: L.H. Pearl, Department of Biochemistry, 
University College London, Gower Street, London WCIE 6BT, UK 
Cerulenin was purchased from Sigma Chemical Co. and 
CalBiochem. The synthetic peptide SQNYP1V (Ser-Gln-Asn-Tyr- 
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Pro-lle-Val) was a gift from Dr R. Mertz, Munich. HIV-I proteinase 
was expressed in bacteria harbouring a plasmid constructed from the 
proteinase s quence from HIV-I (strain BHI0) and an MS2 expres- 
sion vector, and partially purified as described [15,16]. The gag 
substrate was produced as an MS2-gag fusion protein as described 
[15]. Reverse transcriptase, consisting mainly of the 66 kDa form, 
was isolated and purified as described [17] from a bacterial lysate 
generously supplied by Dr Gary Tarpley, MI, USA. The pol gene was 
expressed by a ptac vector essentially as described [18]. Endothiapep- 
sin was purified as described [19]. The endothiapepsin ubstrate 
RALPH (Pro-Pro-Thr-Ile-Phe-Phe(NO2)-Arg-Leu) was synthesised 
as described [20]. The aspartic proteinase competitive inhibitor 
L-363,980 was a gift from Drs Boger and Jacobs of Merck, Sharp and 
Dohme Research Labs, USA. The inhibitor has an apparent Ki for 
endothiapepsin and RALPH, of 15 nM. 
Peptide cleavage assays were p formed in a total volume of 20/A, 
containing 2/A of the heptapeptide SQNYPIV (20 mM), 5/zl of par- 
tially purified proteinase (Ultrogel peak fraction, see [16]) in a stan- 
dard MGTE Buffer (15 mM Mes, pH 6.0, 15% (w/v) glycerol, 0.08% 
(v/v) Triton X-100, 4 mM EDTA, pH 7.0). Incubation was for 2 h 
at 37°C. Inhibition by cerulenin was performed by preincubation of 
the proteinase in the presence of cerulenin in the conditions described 
above, but from which the peptide substrate was omitted. Cerulenin 
was dissolved in dimethyl sulphoxide (DMSO), and used at the con- 
centrations indicated in the results. The final concentration ofDMSO 
was 2.5% in the assay. Preincubation was for 30 rain at 37°C. The 
cleavage reaction was started by addition of peptide substrate. Pep- 
tide cleavage was analysed by HPLC as described [16] and the in- 
tegrated areas of the peaks corresponding to the cleavage products 
and residual substrate were used to calculate the percentage of 
cleavage shown in the results. 
Cleavage of HIV-1 gag was performed using bacterial lysate from 
bacteria expressing the HIV-1 gag sequence as part of an MS2-gag fu- 
sion protein [15]. The inhibition assay was performed by incubation 
in a total volume of 40/zl of 15 mM Mes, pH 6.0, buffer, 5/A pro- 
teinase and cerulenin (dissolved in DMSO) at the concentrations 
shown in the results. After preincubation for 30 rain at 37°C, 1/zl of 
bacterial lysate containing gag was added, the volume adjusted to 
50/A, and incubated at 37°C for 2 h. Cleavage ofgag in the bacterial 
lysate was monitored by immunoblot using a monoclonal antibody 
recognising the MS2 portion of the MS2-gag fusion protein used for 
gag expression [15]. Cleavage assays of purified reverse transcriptase 
in the presence of cerulenin were p rformed by an essentially identical 
procedure but using 3/A of purified reverse transcriptase as the 
substrate. Cleavage of p66 to p51 is specifically achieved by the 
purified HIV-1 proteinase in vitro, which generates approximately 
equimolar amounts of p66 and p51, and no further cleavage products 
even during overnight incubation (Moelling et al., unpublished obser- 
vations). Cleavage of p66 to p51 was monitored by immunoblot using 
a monoclonal antibody against HIV-1 reverse transcriptase [15]. 
Inhibition of peptide cleavage by endothiapepsin was performed by 
preincubating 100 g of endothiapepsin with 5 mg of cerulenin in 
1.0 ml of 0.1 M sodium acetate, pH 5.0, containing 30% DMSO. En- 
dothiapepsin activity was assayed by following the cleavage of the 
chromogenic substrate Pro-Pro-Thr-Ile-Phe-Phe(NOz)-Arg-Leu 
spectrophotometrically at 300 nm at pH 5.0 as described [20]. Con- 
trol samples were incubated simultaneously, including a sample con- 
taining the competitive inhibitor L-363,980 at a final concentration of
440 nM. 
3. RESULTS 
The effect of  cerulenin was measured in 3 systems: 
cleavage of  a bacter ial ly expressed gag precursor pro- 
tein, cleavage of  the 66 kDa form of  HIV-1 reverse 
transcr iptase, and cleavage of  a synthetic peptide, 
SQNYPIV ,  which is the sequence observed at the junc- 
t ion of  p17 and p24 in the HIV-1 gag polyprotein.  The 
pept ide is cleaved at the Tyr -Pro  (YP) bond. 
The abil ity of  HIV-1 proteinase to cleave the syn- 
thetic substrate SQNYPIV ,  was progressively reduced 
by preincubat ion with increasing concentrat ions of  
cerulenin ( f ig . lA) ,  giving an approx imate IC5o of 
2.5 mM. The activity of  the enzyme alone or with 
DMSO at the concentrat ion used (2.5%), was not 
reduced over this incubat ion per iod (controls not 
shown). 
The effect of  cerulenin on HIV-1 proteinase cleavage 
of  the HIV-1 gag polyprote in  was assayed using an E. 
coli expressed MS2-gag fusion protein as substrate, 
with cleavage moni tored by immunoblot  using a 
monoc lonal  ant ibody against the MS2 moiety. Protein 
detected by this method corresponds to the amino-  
terminal  p17 (MA) domain  of  the gag polyprotein.  
Generat ion of  p17 is s ignif icantly decreased by prein- 
cubat ion of  the proteinase with cerulenin at 5 -10  mM, 
and completely abol ished by 20 mM. Product ion  of  
several bands which are intermediate in molecular  
weight between the MS2-Pr55 g"g and the MS2-p I7  g"g is 
also abol ished. 
As a third substrate, the 66 kDa form of  HIV-1 
reverse transcr iptase was used. When puri f ied f rom a 
bacter ial ly expressed ptac-pol construct by the method 
of  Hansen et al. [17], this predominant ly  consists of  
p66 [18] and smaller intermediates,  but no p51. Incuba- 
t ion with the HIV-1 proteinase in vitro produces one 
predominant  cleavage product  which comigrates with 
RT-p51 ( f ig. lC) .  This suggests that in HIV-1,  the pro-  
teinase may be responsible for generating the reverse 
transcr iptase heterodimer as descr ibed previously in 
other retroviruses [21]. This cleavage can also be per- 
formed by other proteinases [22] suggesting that the 
p51/RNase  H junct ion has a structure part icular ly 
susceptible to proteolysis.  Cleavage of  the p66-RT to a 
molecule comigrat ing with p51, was also signif icantly 
inhibited by cerulenin at concentrat ions around 5 mM 
(fig. 1C) and effectively abol ished by 20 mM cerulenin. 
Wi th  the gag and pol  substrates, no cleavage was 
observed in the absence of  proteinase, and cleavage was 
not inhibited by pre incubat ion of  the proteinase alone 
or with DMSO.  With all 3 substrates, inhibit ion of  pro- 
teinase activity required pre incubat ion with cerulenin. 
To determine whether inhibit ion by cerulenin is a 
specific property  of  retroviral  aspart ic proteinases or a 
property  of  aspartic proteinases in general, we have ex- 
amined the effect of  cerulenin on a well-characterised 
aspart ic proteinase of  known structure, endothiapep-  
sin. Incubat ion of  endothiapepsin with cerulenin results 
in progressive loss of  its proteolyt ic activity against a 
pept ide substrate, with 50% inactivat ion after 3 h in- 
cubat ion with 5 mg/ml  (20 mM) cerulenin (fig.2). 
When the active-site-directed competit ive inhibitor 
L-363,980 was included in the preincubat ion,  the rate 
of  inact ivat ion was 1.5 times slower. 
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Fig.1. (A) Cleavage of the synthetic heptapeptide (SQNYPIV) 
corresponding tothe p17/p24 junction of HIV-1 gag, by the partially 
purified HIV-1 proteinase, in the presence of the indicated 
concentrations of cerulenin. Cleavage was monitored by HPLC and 
the areas of the peaks corresponding to substrate and products were 
integrated to calculate the percentage cleavage. (B) Cleavage of 
bacterially expressed MS2-gag fusion protein (indicated as pr55gag), 
by the partially purified HIV-1 proteinase, in the presence of the 
indicated concentrations of cerulenin. Cleavage was analysed by 
immunoblotting using a monoclonal antibody against the MS2 
moiety of the MS2-pl7 fusion protein. Control reactions were 
performed by using the proteinase with and without DMSO (+/ -  
DMSO), with and without preincubation, and by omitting the 
proteinase itself. M indicates marker proteins, from top to bottom: 
92, 68, 43, 34 kDa. (C) Cleavage of the purified p66 reverse 
transcriptase to p51 by the partially purified HIV-1 proteinase, in the 
presence of the indicated concentrations of cerulenin. Reaction 
products were analysed by immunoblot using a monoclonal antibody 
against the p66/p51 RT. Control reactions are as indicated and 
explained in fig. 1B. p66/51 indicates a purified RT consisting of the 
naturally occurring heterodimer. M indicates marker proteins (see 
fig.lB); i indicates intermediates between p66 and p51. 
4. STRUCTURAL BASIS OF PROTEINASE 
INHIB IT ION BY CERULENIN 
Inactivation of retroviral and pepsin-like aspartic 
proteinases by cerulenin, suggests that cerulenin is ac- 
ting via the same mechanism in both. There is very little 
sequence homology between these two types of en- 
zymes, except in the regions which form the active sites, 
which are virtually identical [6]. It seems reasonable to 
argue that cerulenin's inhibitory action occurs at the ac- 
tive site of both types of enzymes, rather than by some 
allosteric mechanism• This is supported by the observa- 
tion that he rate of inactivation by cerulenin can be 
slowed by the presence of an active-site directed com- 
petitive inhibitor• 
The structure of the cerulenin molecule (fig.3A), 
shows several features which explain its activity as an 
aspartyl proteinase inhibitor• The presence of an epox- 
ide function in cerulenin is reminiscent of a similar 
function in a known aspartyl proteinase inhibitor, 
EPNP [23] (1,2-epoxy-3-nitrophenoxy-propane) 
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Fig.2. Percentage remaining activity of endothiapepsin for cleavage 
of chromogenic substrate after incubation with cerulenin at5 mg/ml, 
as a function of time. Open circles are incubation with cerulenin 
alone; closed circles are incubation with cerulenin and the 
competitive inhibitor L-363,980. 
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Fig.3. (A) Structure of cerulenin ((2S,3R)2,3-epoxy-4-oxo-7,10- 
dodecadienoylamide). (B) Structure of EPNP (1,2-epoxy-3-nitro- 
phenoxy propane), a classic covalent in ctivator of aspartic 
proteinases. 
(fig.3B), which irreversibly inactivates aspartyl pro- 
teinases by esterification f the two active-site aspartic 
acid residues [24], and has been shown to inactivate 
recombinant HIV-1 proteinase [25]. The rate of inac- 
tivation of endothiapepsin by cerulenin is comparable 
to that observed for its inactivation by EPNP. 
Crystal structures of complexes between aspartyl 
proteinases and peptide-based inhibitors [26-28] show 
certain hydrogen bonding contacts to be critical for the 
correct positioning of the inhibitor (and presumably the 
substrate) relative to the active-site residues (fig.4). In- 
terestingly, the cerulenin molecule possesses several of 
the groups necessary for formation of these hydrogen 
bonds. When model-built into the active site of the 
crystal structure of endothiapepsin [29,30], the ter- 
minal amide group of cerulenin can form both of the 
/ 
Fig.4. Computer g aphics model of cerulenin docked in the active site 
of endothiapepsin. The dotted lines indicate possible hydrogen bonds 
between the enzyme and groups on the cerulenin molecule. The
epoxide ring is positioned such that it could react with the carboxyl 
side chain of one of the catalytic aspartates, 32 and 215. The 
lipophilic tail, which probably helps cerulenin to cross the cell 
membrane, lies in the substrate-binding cleft interacting with the 
residues that form the hydrophobic P1(and possibly P3) binding site. 
hydrogen bonds which serve to position the P1 and P I '  
residues of a substrate such that the scissile bond is cor- 
rectly orientated relative to the catalytic aspartic acid 
residues. When positioned in this way, the 4-oxo group 
of cerulenin occupies the same position as the carbonyl 
group of the scissile peptide bond of a substrate, with 
the reactive 2,3-epoxide group close to the position of 
the amide nitrogen of the substrate scissile peptide 
bond (fig.5A,B). The result of any of the catalytic 
mechanisms proposed for aspartic proteinases [31-33] 
on cerulenin thus positioned, would be the esterifica- 
tion of one of the catalytic active-site aspartate 
residues, resulting in the inactivation of the enzyme. A 
covalent mechanism for proteinase inhibition by 
cerulenin, is entirely consistent with our observation 
that inhibition requires preincubation with the enzyme, 
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Fig.5. Comparison fthe interactions of a peptide substrate (A) and 
cerulenin (B), with groups in the active site ofan aspartic or retroviral 
proteinase. The numbers in brackets refer to the residues in the 
dimeric HIV-1 proteinase which correspond to the catalytic 
aspartates (32 and 215), and the conserved glycines (34 and 217) of 
the archetypal pepsin family. 
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and that  the degree of inhibit ion depends on t ime of  in- 
cubat ion  as well as inhibi tor  concentrat ion.  Cerulenin 
is perhaps better described as a retroviral  proteinase 
' i nac t ivator ' .  
The very high degree of similarity between the active- 
site structure of  endoth iapeps in  and that of the 
retrovira l  proteinases (A. Wlodawer ,  personal  com- 
municat ion) ,  suggests that cerulenin would bind in a 
virtual ly identical manner  in the HIV-1 prote inase to 
the model  presented here. 
5. CONCLUSION 
In l ight of  our  in vitro observat ions,  it is probable  
that  a ma jor  component  of cerulenin's  inhibit ion of gag 
cleavage in infected cell culture, is due to inact ivat ion 
of  the viral proteinase.  However ,  at higher concentra-  
t ions,  cerulenin appears to inhibit processing of  the env  
precursor  [11,13], which is not cleaved by the viral pro- 
teinase. It is possible that at these higher levels, 
cerulenin is inhibit ing cellular aspart ic proteinases such 
as cathepsins D and E, which may be involved in env  
processing. The inhibit ion by cerulenin of  ant igen pro- 
cessing in ant igen presenting cells [14], may be due to 
a similar effect. 
Ceru lenin  displays a broad range of effects, in- 
hibit ing proteinase activity, g lycosylat ion,  and fatty 
acylat ion.  This lack of  specificity, and a degree of 
cytotoxic i ty,  make cerulenin itself an inappropr ia te  
candidate  for clinical use. However ,  cerulenin's  anti- 
prote inase activity will al low the design of prote inase 
inact ivators incorporat ing some of  the structural  
features of  cerulenin. 
Additional note: After submission of this manuscript, Blumenstein et
al. [34] reported inhibition of HIV-1 proteinase cleavage of small 
peptides by cerulenin, and several synthetic analogues. In their 
system, cleavage of peptide was only evaluated after incubation of 
enzyme, substrate and inhibitor for 16 h and longer. In this system 
they did not observe the n ed for preincubation with inhibitor, which 
we find with our much shorter incubations with substrate. 
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